PDCD1 and lung cancer: Previous studies have correlated TCR repertoire diversity with responses to ICI therapy and shown increased TCR diversity following anti–PD-L1 and anti–PD-1 therapy in responders and patients with longer OS in non–small cell lung cancer and Merkel cell carcinoma (36, 37).